Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7123520 adjunct treatment study in rheumatoid arthritis after inadequate response to TNF-alpha inhibitors
2016-002126-36Phase 2Terminated
- Sponsor
- Roche
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing RO7123520 + methotrexate + TNF-alpha inhibitor with Placebo + methotrexate + TNF-alpha inhibitor (2 arms). Primary endpoint: Incidence of adverse events. Started Nov 2016; status: terminated.
02
Drugs
RO7123520
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-002126-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002126-36.